Trial reportReproductive sciences (Thousand Oaks, Calif.)2025
Effects of Testosterone on Cumulus Cells Gene Expression in Patients with Diminished Ovarian Reserve.
Trial report in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diminished ovarian reserve represents a challenging condition in assisted reproductive technology. Androgens' actions are recognized as instrumental in folliculogenesis based on animal and human studies. Thus, we aimed at investigating whether testosterone pretreatment has an influence on gene expression of cumulus cells of diminished ovarian reserve patients. We included patients under 42 years-old presenting for IVF with diminished ovarian reserve (antral follicle count ≤ 6 and antimüllerian hormone < 1.2 ng/ml), between may/2018 and august/2019. Stratified randomization was performed and subjects were allocated into testosterone group (receiving transdermal testosterone gel pretreatment 1% 25 mg daily; N = 9) or control group (receiving standard ovarian stimulation; N = 9). Cumulus cells were collected following oocyte retrieval and RT-qPCR was conducted to evaluate gene expression differences in members of AKT signaling pathway, mTOR signaling pathway, IGF1, FSHR and AMH. Testosterone group patients showed a lower expression of AKT1 in cumulus cells as compared to control group subjects. Other evaluated target genes of the same pathway (FOXO1, FOXO3, PTEN), mTOR signaling pathway genes (mTOR, TSC1, TSC2), as well as IGF1, FHSR and AMH displayed no significant differences between groups. Testosterone pretreatment in diminished ovarian reserve patients down-regulates AKT1 gene expression in cumulus cells. The described profile could be linked to better oocyte reproductive potential, as cumulus cells related to competent oocytes might decide their fate (apoptosis) after completing their role in sustaining oocyte development during cyclic follicular recruitment. Transdermal testosterone pretreatment in diminished ovarian reserve patients down-regulates AKT1 in cumulus cells, possibly enhancing oocyte reproductive potential.
Indexed as
Identifiers
40588714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.